Are the progestins responsible for breast cancer risk during hormone therapy in the postmenopause?: Experimental vs. clinical data
- 31 March 2008
- journal article
- review article
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 109 (1-2) , 11-15
- https://doi.org/10.1016/j.jsbmb.2007.12.002
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Effects of Conjugated Equine Estrogen in Postmenopausal Women With HysterectomyJAMA, 2004
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Effect of Hormone Replacement Therapy on Breast Cancer Risk: Estrogen Versus Estrogen Plus ProgestinJNCI Journal of the National Cancer Institute, 2000
- Menopausal Estrogen and Estrogen-Progestin Replacement Therapy and Breast Cancer RiskJAMA, 2000
- Characterization of paired tumor and non-tumor cell lines established from patients with breast cancerInternational Journal of Cancer, 1998
- Effects of two classes of progestagens, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells: I. MCF-7 cell linesThe Journal of Steroid Biochemistry and Molecular Biology, 1995
- Growth Factors in Breast CancerEndocrine Reviews, 1995
- Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanismBritish Journal of Cancer, 1993
- Advances in Diagnostic Imaging and Overestimations of Disease Prevalence and the Benefits of TherapyNew England Journal of Medicine, 1993
- Effects of progestins on the proliferation of estrogen-dependent human breast cancer cells under growth factor-defined conditionsThe Journal of Steroid Biochemistry and Molecular Biology, 1992